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Abstract
Adenosine is well known to be released during cerebral
metabolic stress and is believed to be neuroprotective. ATP
release under similar circumstances has been much less
studied. We have now used biosensors to measure and
compare in real time the release of ATP and adenosine during
in vitro ischaemia in hippocampal slices. ATP release only
occurred following the anoxic depolarisation, whereas
adenosine release was apparent almost immediately after the
onset of ischaemia. ATP release required extracellular Ca
2+.
By contrast adenosine release was enhanced by removal of
extracellular Ca
2+, whilst TTX had no effect on either ATP
release or adenosine release. Blockade of ionotropic glutam-
ate receptors substantially enhanced ATP release, but had
only a modest effect on adenosine release. Carbenoxolone,
an inhibitor of gap junction hemichannels, also greatly
enhanced ischaemic ATP release, but had little effect on
adenosine release. The ecto-ATPase inhibitor ARL 67156,
whilst modestly enhancing the ATP signal detected during
ischaemia, had no effect on adenosine release. Adenosine
release during ischaemia was reduced by pre-treament with
homosysteine thiolactone suggesting an intracellular origin.
Adenosine transport inhibitors did not inhibit adenosine
release, but instead they caused a twofold increase of re-
lease. Our data suggest that ATP and adenosine release
during ischaemia are for the most part independent processes
with distinct underlying mechanisms. These two purines will
consequently confer temporally distinct inﬂuences on neur-
onal and glial function in the ischaemic brain.
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peri-infarct depolarisation.
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The purines ATP and adenosine exert powerful modulatory
inﬂuences in the mammalian central nervous system. ATP
can act at both ligand-gated ATP P2X receptors and G
protein-coupled P2Y receptors, whereas adenosine acts only
through four G protein-coupled receptors (Ralevic and
Burnstock 1998). Purinergic signalling inﬂuences transmitter
release (Dunwiddie and Masino 2001), synaptic plasticity
(Pankratov et al. 2002; Pascual et al. 2005), neurone-glia
interactions (Fields and Burnstock 2006), nociception (Liu
and Salter 2005), sleep-wake cycles (Basheer et al. 2004),
respiratory (Gourine 2005) and locomotor rhythms (Dale and
Kuenzi 1997), anxiety, depression, aggression and addiction
(Fredholm et al. 2005).
Adenosine is well known to be released during cerebral
hypoxia/ischaemia both in vitro and in vivo (Latini and
Pedata 2001; Frenguelli et al. 2003; Phillis and O’Regan
2003). Indirect studies using pharmacological antagonists
(Fowler 1989; Pearson et al. 2006), receptor knockouts
(Johansson et al. 2001) or focal receptor deletion (Arrigoni
et al. 2005) demonstrate that activation of presynaptic
adenosine A1 receptors causes rapid depression of excitatory
synaptic transmission during hypoxia/ischaemia in vitro and
in vivo (Gervitz et al. 2001; Ilie et al. 2006). This conclusion
is strengthened by the close temporal association of adeno-
sine release with the depression of excitatory synaptic
transmission (Frenguelli et al. 2003; Pearson et al. 2006).
Activation of A1 receptors is widely regarded as an important
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(Sebastiao et al. 2001; Arrigoni et al. 2005).
Intracellular ATP falls dramatically during cerebral meta-
bolic stress in vitro (Gadalla et al. 2004) and in vivo (Phillis
et al. 1996). The issue of whether ATP, like adenosine, is also
released during cerebral ischaemia has not been extensively
examined. Direct release of ATP has been demonstrated
in vitro (Juranyi et al. 1999) and in vivo (Melani et al. 2005),
but these HPLC studies lack good spatial and temporal
resolution.Incontrast,somestudieshavefailedtodemonstrate
ATP release (Phillis et al. 1993). Indirect evidence, such as
extracellular metabolism of nucleotides to adenosine (Koos
et al. 1997) or the post-ischaemic up-regulation of ATP
metabolising ectoenzymes (Braun et al. 1998) is suggestive
of ATP released during metabolic stress. However, unlike
adenosine release, the timing, dynamics and quantity of ATP
release during ischaemia has not been documented.
In this paper, we have used enzyme-based microelectrode
biosensors (Frenguelli et al. 2003; Dale et al. 2005; Llaudet
et al. 2005) to measure simultaneously the real-time release
of adenosine and ATP during ischaemia in rat hippocampal
slices. This has allowed us to study in detail the quantity,
timing and mechanisms of ATP release. We ﬁnd that ATP is
released only following the anoxic depolarisation, well after
the initial release of adenosine. Relatively small quantities of
ATP are released compared with adenosine and the mech-
anisms of ATP and adenosine release are quite distinct.
Methods
Electrophysiology
Extracellular recordings were made from area CA1 of 400 lm
hippocampal slices from 11–16 and 22–27 days old Sprague-Dawley
rat pups. Slices, prepared as described previously (Dale et al. 2000),
were suspended on a mesh and submerged in aCSF ﬂowing at 5–
6 mL/min at 33–34 C. Field excitatory postsynaptic potentials
(fEPSPs) were recorded, with aCSF-ﬁlled glass microelectrodes,
from stratum radiatum of area CA1 in response to stimulation (at 15 s
intervals; bipolar Teﬂon-coated tungsten wire) of the Schaffer
collateral-commissural ﬁber pathway. ‘Blind’ whole-cell patch
clamp recordings were made in current-clamp mode from CA1
pyramidal neurones using pipettes (5–7 MW) containing (in mmol/
L): K-gluconate, 130; KCl, 10; CaCl2, 2; EGTA, 10; HEPES, 10; pH
7.27, adjusted to 295 mOsm.
Standard aCSF contained (in mmol/L): NaCl, 124; KCl, 3; CaCl2,
2; NaHCO3, 26; NaH2PO4, 1.25; D-glucose, 10; MgSO4, 1; pH 7.4
with 95% O2/5% CO2 and was gassed with 95% O2/5% CO2.I n
‘ischaemic’ aCSF, 10 mmol/L sucrose replaced the 10 mmol/L D-
glucose and was equilibrated with 95% N2/5% CO2 (Frenguelli
1997; Pearson et al. 2006). As previously reported, (Dale et al.
2000), this substitution of N2 for O2 caused a rapid decrease in the
bath oxygen tension from approximately 80–90% saturation to
<10%. The recording and analysis of fEPSPs was under the control
of LTP software (courtesy of Dr Bill Anderson & Professor Graham
Collingridge, University of Bristol, http://www.ltp-program.com/
indexLtp24.htm (Anderson and Collingridge 2001)). For the most
part, electrical recordings were ﬁltered between 1 Hz and 3 kHz
(sampling frequency 10 kHz), but to record accurately the extracel-
lular potential shifts associated with the anoxic depolarisation,
continuous DC ) 3 kHz recordings were also made using the custom
software package used to record sensor signals (see below).
ATP and adenosine sensors
The principles and operation of the Pt/Ir microelectrode biosensors
for the purines, ATP and adenosine, have been described previously
(Frenguelli et al. 2003; Llaudet et al. 2003, 2005). These biosensors
have been used to record: release of ATP from spinal cord during
locomotion (Llaudet et al. 2005); release of ATP in the developing
retina (Pearson et al. 2005) and release of ATP from the ventral
medulla oblongata during hypercapnia (Gourine et al. 2005a) and
hypoxia (Gourine et al. 2005b). The biosensors in this study were
obtained from Sarissa Biomedical (www.sarissa-biomedical.com;
Coventry, UK) and were a development of those previously
described in that the Pt/Ir microelectrode was coated with a
permselective polymer prior to enzyme matrix deposition. This
‘screening layer’ greatly improves the selectivity of the biosensors
by reducing any contribution to the signal by electroactive
interferents such as ascorbate, 5-HT or noradrenaline. Before
insertion and after removal of the sensors from the slice, the
sensors were calibrated with 10 lmol/L ATP, adenosine and 5-HT,
the latter being used to assess the patency of the screening layer.
To give a measure of net ATP concentrations the signal from a
‘Null’ sensor (lacking enzymes, but otherwise identical) was used to
measure background signals, which were then subtracted from the
signals generated by the ATP biosensor. For the adenosine sensor, a
separate ‘inosine’sensor, lacking adenosine deaminase, is required to
yield a signal speciﬁc to adenosine (Frenguelli et al. 2003). To limit
the number of sensors inserted into the slice, this additional sensor
was largely omitted. Thus, the signal recorded from the adenosine
sensor can be described as that from both adenosine and inosine (ado/
ino). From previous studies, we have estimated that approximately
50% of the signal from the ado/ino biosensor is due to inosine (Dale
et al. 2000; Frenguelli et al. 2003). To take into account that
biosensor sensitivity varies during different experiments, we have
used the calibration of the sensor to adenosine to normalise the
signal. We report the values in lmol/L¢ to indicate that the signal is
normalised to sensitivity but cannot be literally interpreted in units of
concentration for adenosine or inosine but is a mixture of the two
substances. The ado/ino signal displays a negative-going deﬂection
during the onset of ischaemia that reﬂects a slight sensitivity to O2
sensitivity of the background current of the sensor, and not a decrease
in extracellular adenosine (Frenguelli et al. 2003).
ATP, Null and ado/ino biosensors were each inserted through the
400 lm thickness of the slice such that most of the sensing part of
the sensors was in intimate contact with the tissue. We have
previously shown that this is not detrimental to the slice and that
fEPSPs can be recorded with the sensors in place, and indeed
directly from the sensors (Frenguelli et al. 2003). Additionally, the
stimulating and recording electrodes were placed adjacent to the
sensors. Continuous signals from the sensors and recording
electrode were acquired at 10 kHz using a custom software package
and displayed on a PC. The software allowed post-hoc compensa-
tion for any differences in sensor sensitivity and subtractions to be
ATP release during ischaemia 1401
  2007 The Authors
Journal Compilation   2007 International Society for Neurochemistry, J. Neurochem. (2007) 101, 1400–1413performed to yield net ATP signals, which were expressed in
absolute units of concentration (lmol/L).
Experimental protocols
Drugs were bath applied to the slice and sufﬁcient time, at least
15 min, was allowed for their equilibration through the tissue. Drugs
were either applied as aliquots from stock solutions or dissolved
directly into the aCSF (kynurenic acid, carbenoxolone, EGTA,
homocysteine thiolactone). Ca
2+-free aCSF comprised aCSF to
which no Ca
2+ was added, but contained an extra 2 mmol/L Mg
2+ to
maintain the concentration of divalent cations. To further reduce
extracellular Ca
2+, 1 mmol/L EGTA was added to this nominally
Ca
2+-free aCSF.
Malachite Green phosphate assay and measurement
of ectonucleotidase activity in slices
To assess endogenous ectonucleotidases activity in hippocampal
slices and the efﬁcacy of ARL 67156 as a blocker, we used the
convenient phosphate assay of Carter and Karl (1982).
Hippocampal slices (400 lm thickness) were prepared from 24–
26 days male Sprague-Dawley rats. They were carefully dissected
free from the cortex, thalamus and globus pallidus and kept in
oxygenated aCSF solution at room temperature for 1 h prior to
being placed into individual wells in a 24 well plate. The
hippocampal slices were then washed ﬁve times with phosphate-
free aCSF (comprising (in mmol/L): KCl, 3.1; NaCl, 126; NaHCO3,
26; D-glucose, 10; CaCl2, 1; MgCl2, 2).
The slices (one per well) were then immersed in 400 lL of test
solution (phosphate-free aCSF with either 10, 50 or 100 lmol/L
ATP). 5% CO2 and 95% O2 was blown across the surface of each
well to prevent hypoxia. The multi-well plate was placed on a shaker
sothat there was gentle agitation of the slices and good mixing within
the wells. To maintain the health of the slices each experimental run
was restricted to 30 min, with 25 lL aliquots being removed at 0, 1,
3, 5, 10, 15, 20, 25 and 30 min for phosphate analysis.
The rate of phosphate production (measured from the slope of the
graph of [phosphate] versus time) was compared in the control to the
rate in the presence of ARL 67156. A timed control was also
performed whereby the rate of phosphate production was compared
for two successive runs without the addition of ARL 67156. This
resulted in a small reduction of the rate of phosphate production
between runs of 9.8 ± 3.3% (n = 16). This small decrease in the
control was subtracted from the decreases caused by ARL 67156 to
give the net reduction in phosphate production due to the inhibition
of the ectoATPases.
Drugs
The salts used in the aCSF were obtained from Fischer. EGTA,
kynurenic acid, carbenoxolone, ouabain, S-(4-Nitrobenzyl)-6-thio-
inosine (NBTI), dipyridamole (DIPY), L-homocysteine thiolactone,
adenosine, inosine and 5-HT were from Sigma–Aldrich. TTX was
purchased from Alomone Labs, ARL 67156 from Tocris and ATP
from Boehringer.
Data analysis and statistics
Data are expressed as mean ± SEM and were pooled and compared
using unpaired t-tests. Computed signiﬁcance values are given
where appropriate.
Results
Estimates of basal adenosine and ATP concentrations
in area CA1 of hippocampal slices
The selectivity of the biosensors versus common interfer-
ences found in the brain makes it possible to estimate the
basal tone of adenosine and ATP in the slice. As the
electrochemical sensors have a background current this
determination can most conveniently be performed via a two-
stage method, by ﬁrst inserting the sensor into the slice,
allowing it to equilibrate for at least 30 min and then
measuring the change in current observed when the sensor is
pulled from the slice. To convert this change in current to
absolute concentration of adenosine or ATP we used an
inosine and null sensors, respectively, as references for the
adenosine and ATP measurements.
In slices that had not been subjected to ischaemia, there
was no detectable ATP tone (n = 4). Similarly, in 3/4 slices
no detectable adenosine tone could be measured (although a
tone of 210 nmol/L was measured in one slice). The inability
to consistently detect the adenosine tone, readily observable
on excitatory synaptic transmission through the use of
adenosine A1 antagonists is possibly because of the limita-
tions of the two-stage measuring method, as pharmacological
manipulations to reduce the breakdown of ATP consistently
revealed a loss of adenosine tone (see later). However, in
slices that had been subjected to ischaemia, when measured
some 30 min following the end of the ischaemic episode, an
adenosine tone was detectable (mean 340 ± 130 nmol/L,
n = 6; see also Pearson et al. 2006). An ATP tone (2.5 and
0.1 lmol/L) was measured in 2/6 slices that had been
exposed to ischaemia.
Differential release of adenosine and ATP during
ischaemia
To mimic the oxygen/glucose deprivation that occurs during
in vivo ischaemia, we switched the superfusate of hippo-
campal slices from a control aCSF to an ‘ischaemic’ aCSF
that had been pre-equilibrated with N2 and lacked D-glucose.
The mean duration of the ischaemic episodes given under the
various experimental conditions is provided in Table S1.
As previously described (Frenguelli 1997; Pearson et al.
2006), this resulted in a rapid depression of excitatory
synaptic transmission (<10% of control after 3 min of
ischaemia, n = 13). The ado/ino biosensor exhibited a
rapidly increasing current, which reached 338 ± 36 pA
(n = 18) at 5 min (Figs 1a and b; cf. Frenguelli et al.
2003). By contrast, no change in current was recorded on
either the ATP or Null biosensors at 5 min (n = 19; Figs. 1a
and b). Thus, the signal recorded by the ado/ino biosensor
represented a speciﬁc purine nucleoside signal and was
equivalent to 3.3 ± 0.4 lmol/L¢ (Table 1). This conﬁrms
previous observations of the dominant role of adenosine in
1402 B. G. Frenguelli et al.
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mission (Fowler 1989; Johansson et al. 2001; Arrigoni
et al. 2005; Pearson et al. 2006). Our observation of ado/
ino release in the apparent absence of ATP release during
ischaemia suggests that the majority of extracellular
adenosine does not arise from the prior release and
degradation of ATP.
As the period of ischaemia was prolonged (Fig. 1a), the
neurons in the slice went through a phenomenon termed the
‘anoxic depolarisation’ or ‘hypoxic spreading depression’
(Somjen 2001). The anoxic depolarisation was detected as
loss of the presynaptic ﬁber volley rapidly followed by a
large negative deﬂection on the extracellular DC trace.
Ado/ino release continued to increase to the point of the
anoxic depolarisation reaching 8.9 ± 0.8 lmol/L¢. However,
ATP was only released following the anoxic depolarisation,
reaching a concentration of 0.7 ± 0.2 lmol/L at the point of
re-oxygenation (usually 2–4 min following the anoxic
depolarisation). By contrast ado/ino release either reached a
plateau following the anoxic depolarisation or began to
decline (overall the signal was 9.2 ± 0.7 lmol/L¢ at the
moment of re-oxygenation).
Following re-oxygenation we observed a surge in ado/ino
release (previously reported as the post-hypoxic purine
Fig. 1 Real-time measurement of the release of ATP and adenosine
during ischaemia in vitro. (a) Simultaneous recordings from adeno-
sine/inosine (Ado/ino), ATP and null biosensors, the fEPSP (in AC
mode) and extracellular DC potential. Ischaemia (black bar) caused
the rapid depression of the fEPSP (disappearance of the periodic
negative deﬂections on the traces), which was associated with a rise in
extracellular adenosine. Little change is seen in the ATP signal in the
early stages of ischaemia. As the ischaemic episode progressed the
anoxic depolarisation occurred (large negative deﬂection on DC trace;
dashed vertical line). ATP release followed the anoxic depolarisation.
Re-oxygenation resulted in a characteristic surge of adenosine release
(the post hypoxic/ischaemic efﬂux; PPE; arrowhead) and, to a lesser
extent, of ATP (arrowhead). Synaptic transmission did not recover
after the ischaemic episode in this slice. Magniﬁed examples of the
fEPSP shown at the times indicated on the continuous DC trace are
shown. The arrow indicates the ﬁbre volley. Note that this has disap-
peared in trace (iii) (asterisk), obtained shortly after the anoxic depo-
larisation. On re-oxygenation, the ﬁbre volley was usually enhanced
(iv). (b) A short period of ischaemia (black bar), insufﬁcient to evoke
the anoxic depolarisation, did not elicit ATP release, but a substantial
amount of adenosine was released both during and after the ischae-
mic episode. Note that full recovery of the fEPSP occurred. The rapid
periodic deﬂections on the biosensor traces are a combination of fE-
PSP and artefacts from the stimulating electrode used to evoke the
fEPSP. The negative deﬂection on the Ado/ino trace arises from re-
moval of oxygen and does not represent a fall in extracellular
adenosine/inosine concentration. In this and subsequent ﬁgures the
ATP sensor trace reﬂects net ATP, i.e. the signal after subtraction of
the simultaneously-recorded null sensor.
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of 22.7 ± 1.6 lmol/L¢ (Fig. 1a, Table 1). A much smaller
and shorter-lasting version of the PPE was observed on the
ATP biosensor signal that reached a peak of 1.8 ± 0.2 lmol/
L and rapidly fell back to baseline. By contrast with the
ado/ino and ATP biosensor signals, the Null sensors recorded
only small currents at the point of the anoxic depolarisation
(20 ± 4.7 pA; n = 19; Fig. 1a) and at the moment of re-
oxygenation (63 ± 10 pA), with no evidence of a surge in
current following re-oxygenation. The signals recorded
by the ATP and ado/ino sensors are thus most likely the
result of their speciﬁc analyte rather than a non-speciﬁc
interferent.
Shorter episodes of ischaemia (Fig. 1b, n = 4), which did
not progress to the anoxic depolarisation, conﬁrmed that
ado/ino release can be observed in the apparent absence of
any ATP release – no ATP release was seen either during
ischaemia or following re-oxygenation, in stark contrast to
the large ado/ino signal at these time points.
Interestingly, we found that ATP release during ischaemia
was sensitive to age. In studies where we made a direct
comparison, the peak of ATP release following re-oxygen-
ation was 0.8 ± 0.3 lmol/L (n = 6) in slices derived from
11–15 days rats and 2.4 ± 0.8 lmol/L (n = 8) in slices
derived from 22–27 days rats (p = 0.069, one-sided t-test;
data not shown). In these experiments, the anoxic depolari-
sation and ATP release occurred later in the younger animals
(14.2 ± 1.6 min; n = 4) compared with the older group
(7.9 ± 0.7 min; n =4 ;p = 0.007).
The association between the anoxic depolarisation and
ATP release was further strengthened by the use of ouabain,
an inhibitor of the Na
+/K
+-ATPase, which mimics the anoxic
depolarisation (Tanaka et al. 1997) and is used to elicit
anoxic depolarisation-like events in brain tissue (Joshi and
Andrew 2001). Oubain (100 lmol/L; n = 2; data not shown)
rapidly elicited an anoxic depolarisation-like negative shift
on the DC trace and simultaneously caused an increase in
both extracellular ado/ino and ATP.
Whole cell recordings conﬁrm the relationship between
anoxic depolarisation and ATP release
To examine the timing of ATP release with respect to the
anoxic depolarisation in more detail, we performed whole-
cell patch-clamp recordings from CA1 pyramidal neurons
during ischaemia (Fig. 2). These current-clamp recordings
(n = 10) revealed that as the ischaemic episode progressed,
the neurons underwent a slow period of depolarisation that
abruptly increased at the point of the anoxic depolarisation.
ATP release only occurred following this rapid depolarisation
of the neurons.
Table 1 Characteristics of ATP and adenosine release in response to in vitro ischaemia
Net ATP (lmol/L) (lmol/L s) Adenosine (lmol/L¢) (mmol/L¢ s)
Condition AD ReOx PPE Integral n 5 min AD ReOx PPE Integral n
control 0.1 ± 0.1 0.7 ± 0.2 1.8 ± 0.2 897 ± 133 19 3.3 ± 0.4 8.9 ± 0.8 9.2 ± 0.7 22.7 ± 1.6 12.0 ± 1.0 18
Ca
2+-free 0.2 ± 0.1 0.8 ± 0.2 1.2 ± 0.3 756 ± 174 5 10.0 ± 1.2
p = 1.6 · 10
)6
10.9 ± 1.3 8.4 ± 1.3 15.9 ± 2.4
p = 0.051
9.4 ± 0.9 5
Ca
2+-free & EGTA )0.2 ± 0.1 )0.1 ± 0.2 0.4 ± 0.1 85 ± 77
p = 0.004
5 13.7 ± 1.9
p =5· 10
)8
17.1 ± 2.5 9.3 ± 2.7 17.6 ± 2.3 14.1 ± 3.6 6
Kynurenate 0.4 ± 0.2 1.4 ± 0.5 3.7 ± 0.9
p = 0.0064
1317 ± 303 6 2.7 ± 0.6 8.2 ± 1.8 6.1 ± 1.4 18.3 ± 3.7 11.5 ± 3.0 5
TTX 0.2 ± 0.2 1.4 ± 0.2 3.7 ± 0.7
p = 0.0019
1224 ± 430 4 2.6 ± 0.5 9.0 ± 1.2 10.9 ± 1.4 21.7 ± 4.5 12.8 ± 2.8 4





5 6.3 ± 2.4 8.2 ± 2.3 12.2 ± 2.1 35.6 ± 10.4
p = 0.041
13.4 ± 2.4 5
ARL 0.3 ± 0.1 1.1 ± 0.3 3.3 ± 0.7
p = 0.017
1369 ± 317 7 2.7 ± 0.3 7.6 ± 1.0 9.0 ± 1.3 20.7 ± 1.9 10.6 ± 1.7 7
Homocysteine
thiolactone




5 2.4 ± 0.7 7.3 ± 1.2 7.6 ± 1.0 13.8 ± 2.6
p = 0.014
8.2 ± 1.8 5





Measurements of net ATP and adenosine release were made at the time of the anoxic depolarisation (AD), at the time of re-oxygenation (ReOx), at
the peak of the post ischaemic purine efﬂux (PPE). See Figure S1 for annotation of a record showing where the measurements were made.
Additionally, a value for adenosine release at 5 min of ischaemia is given (5 min). Note that at the time of the anoxic depolarisation, there was no
signiﬁcant release of ATP – this occurred progressively following the anoxic depolarisation (reﬂected in the signiﬁcant values seen at the time of re-
oxygenation). The integral was calculated as the area under the curve from the onset of release until 30 min after the end of the ischaemic episode
or until the return of the purine signal to baseline. Data are expressed as mean ± SEM; n refers to the number of slices. Where probability values
are given they were calculated from a two sample t-test comparing the test value to the equivalent control value.
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and Vizi 1996; Bodin and Burnstock 2001; Pankratov et al.
2006), we asked whether the release of ATP during ischaemic
conditions was Ca
2+-dependent.
As an initial test of the Ca
2+-dependency of purine release
during ischaemia we omitted extracellular Ca
2+ and added an
extra 2 mmol/L Mg
2+ to maintain the total concentration of
divalent cations. This modiﬁed aCSF was perfused onto
hippocampal slices (Fig. 3a). As expected, this substitution
caused a complete inhibition of the fEPSP, but also had the
effect of accelerating both the loss of the presynaptic ﬁbre
volley and the anoxic depolarisation (time from onset of
ischaemia to the anoxic depolarisation was 459 ± 18 s in
control and 315 ± 6 s in zero Ca
2+ aCSF (Somjen 2001)). In
these nominally Ca
2+-free conditions, adenosine release still
occurred and indeed was greater than in control conditions
during the early stages of ischaemia, as we have previously
reported with ﬁrst generation adenosine sensors placed on the
surface of the slice (Dale et al. 2000). For example, after
5 min of ischaemia in nominally Ca
2+-free medium the
ado/ino levels were approximately threefold the amount
measured at the comparable time point in standard aCSF
(Table 1). Re-oxygenation resulted in a characteristic surge
of adenosine release, but this was reduced in the Ca
2+-free
aCSF (Fig. 3a, Table 1). Overall, the total amount of
adenosine released (as measured by the integral over the
ischaemic and 30 min post-ischaemic period) was not
different in nominally Ca
2+-free aCSF (Table 1). This
suggests that the PPE was smaller under these conditions
because the enhanced early phases of adenosine release may
have depleted the releasable stores of adenosine (Pearson
et al. 2001, 2006; Frenguelli et al. 2003). ATP release was
no different in nominally Ca
2+-free aCSF compared to
controls (Fig. 3a, Table 1). Re-introduction of Ca
2+ to the
aCSF caused the return of the fEPSP (112.6 ± 17.6% of
baseline; n = 4). Post-ischaemic recovery of the fEPSP was
greatly improved in slices exposed to ischaemia in nominally
Ca
2+-free conditions, compared to controls (7.6 ± 1.1% of
baseline; n = 13), despite the fact that since the anoxic de-
polarisation occurred earlier, the period of ischaemia exten-
ded for longer after its occurrence. This indicates full
functional recovery of the hippocampal circuitry and
suggests that the ATP release observed under these condi-
tions is unlikely to be the result of catastrophic and
irreversible neuronal death, at least over the time-course of
these acute electrophysiological experiments.
Simple substitution of Mg
2+ for Ca
2+ will not remove all
extracellular Ca
2+ and processes requiring only small
amounts of Ca
2+ may still occur. We therefore omitted
Ca
2+ from the perfusion medium (substituted with an
additional 2 mmol/L Mg
2+ as before) and added 1 mmol/L
EGTA to chelate any residual extracellular Ca
2+. This more
radical treatment also speeded the occurrence of the anoxic
depolarisation (326 ± 24 s after the onset of ischaemia;
n = 6). Perfusion of Ca
2+-free/EGTA ischaemic aCSF once
again caused a greater increase in adenosine release during
the early phases of ischaemia compared with the control (Fig.
3b, Table 1). However, the integral of adenosine release
(during and for 30 min after ischaemia) was no different
Fig. 3 Removal of extracellular Ca
2+ reveals mechanistic differences
between ischaemic ATP and adenosine release. (a) Removal of Ca
2+
from the aCSF and substitution by Mg
2+ abolished synaptic trans-
mission, accelerated the anoxic depolarisation (dashed vertical line),
enhanced the early release of adenosine during ischaemia (black bar),
but did not alter ATP release. (b) In contrast, substitution and chelation
of extracellular Ca
2+ with 2 mmol/L Mg
2+/1 mmol/L EGTA, respect-
ively, eliminated ATP release caused by the anoxic depolarisation and
greatly reduced the post-ischaemic efﬂux of ATP.
Fig. 2 Close temporal association between ATP release and the
anoxic depolarisation. Simultaneous extracellular ATP measurement
(upper trace) and whole-cell current-clamp recording of membrane
potential in a CA1 pyramidal neurone (lower trace) during ischaemia
(black bar). Following a gradual depolarisation, during which there was
no change in the signal on the ATP sensor, a rapid membrane
depolarisation (the anoxic depolarisation, dashed vertical line)
occurred provoking repeated action potential ﬁring. ATP release
occurred immediately after the anoxic depolarisation.
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release in Ca
2+-free/EGTA ischaemic aCSF was not sus-
tained, but instead showed some form of depletion.
In contrast to the facilitation of adenosine release by
removal of extracellular Ca
2+, ischaemic ATP release was
essentially eliminated (Fig. 3b and Table 1). ATP and
adenosine release thus have differing sensitivities to extra-
cellular Ca
2+: whereas ATP release depends upon the
presence of extracellular Ca
2+, this acts to inhibit adenosine
release. The simplest explanation for the differential effects
of extracellular Ca
2+ on the release of adenosine and ATP is
that the release of these two purines are independent
processes and that ATP release does not substantially
contribute (through extracellular degradation) to the ado/ino
signal recorded during and following ischaemia.
ATP release is not sensitive to TTX
As ATP release during ischaemia depends upon the presence
of extracellular Ca
2+, we tested whether it might also depend
upon neuronal spiking by applying the Na
+-channel blocker,
TTX at 1 lmol/L. This concentration of TTX was sufﬁcient
to eliminate the presynaptic ﬁbre volley and hence synaptic
transmission. It also took far longer for the slice to pass
through the anoxic depolarisation (851 ± 38 s after the onset
of ischaemia). However, release of ATP following the anoxic
depolarisation with an unchanged magnitude was still
observed (Table 1, Fig. 4). Similarly, adenosine release was
unaffected by the presence of TTX. This further underlines
our observation that ATP release, although Ca
2+-dependent,
appears to occur via a mechanism that is distinct from
conventional synaptic release (which would also be TTX-
sensitive).
ATP release is not blocked by glutamate receptor
antagonism
We used the broad spectrum ionotropic glutamate receptor
antagonist kynurenic acid (5 mmol/L; Fig. 5) to abolish
excitatory synaptic transmission and determine the conse-
quences for ischaemic purine release. In keeping with
previous observations (Pearson et al. 2006), glutamate
receptor antagonism reduced the amount of adenosine by
around 25% during the early stages of ischaemia (Table 1).
As the duration of the ischaemic episode (and hence the
period of adenosine release) was greatly prolonged to ensure
the occurrence of the anoxic depolarisation (see below),
the total amount of adenosine released (the integral) was
indistinguishable from the control (Table 1). These data
suggest that the rate of adenosine production is reduced by
ionotropic glutamate receptor blockade, but that glutamate
receptor activation is not an obligatory requirement for
adenosine release.
Kynurenic acid greatly delayed the anoxic depolarisation
(775 ± 56 s after onset of ischaemia). Despite this increased
delay, the release of ATP (n = 6) still followed the occur-
rence of the anoxic depolarisation (Fig. 5). Strangely, ATP
was released at greatly enhanced levels (Table 1). This
dissociation between the effects of glutamate receptor
blockade on adenosine and ATP release suggests that ATP
release does not contribute appreciably to the accumulation
of extracellular adenosine.
Adenosine and ATP are not released via gap junction
hemichannels
Both connexin and pannexin hemichannels can conduct ATP
(Bao et al. 2004; Theis et al. 2005) and, in the case of
connexins, have been implicated in ischaemic cell death
(Contreraset al.2004;Thompsonet al.2006).Totestwhether
these channels could allow efﬂux of ATP or adenosine during
ischaemic conditions, we applied carbenoxolone (CBX,
100 lmol/L; n = 5) in control aCSF for at least 30 min prior
to an ischaemic episode. CBX caused a gradual inhibition of
the fEPSP that stabilised at 22.9 ± 4.3% of baseline (data not
shown). CBX had little effect on ischaemic adenosine release
(Table 1),however,ATPrelease was greatlyenhanced(Fig. 6,
Table 1). By general consensus, CBX can act at many targets
but the inability of CBX to inhibit either ATP or adenosine
release effectively rules out a contribution of hemichannels to
the release of purines during ischaemia.
Fig. 5 ATP and adenosine release display different sensitivities to
blockade of ionotropic glutamate receptors. In the presence of
5 mmol/L kynurenic acid, the fEPSP was abolished and the anoxic
depolarisation considerably delayed (dashed vertical line). The
amount of adenosine release during and following ischaemia (black
bar) was somewhat reduced, whereas ATP release was greatly
enhanced.
Fig. 4 Adenosine and ATP release during ischaemia persists in
presence of TTX. TTX applied at 1 lmol/L rapidly blocks synaptic
transmission (and in this case causes a fall in the Ado/ino tone). Al-
though the AD is greatly delayed (vertical dashed line) ATP release
still occurs following this event. Adenosine release is unaffected by the
presence of TTX. Black bar denotes period of ischaemia.
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in the extracellular space
The presence of ectonucleotidases that can metabolise ATP
to ADP, AMP and adenosine in the hippocampus is well
known. These enzymes could conceivably play a role in the
production of adenosine during ischaemia. We therefore
tested the efﬁcacy of the endogenous enzymes and their
susceptibility to the ecto-ATPase blocker ARL 67156.
To demonstrate the presence of endogenous ectonucleo-
tidases activity we inserted ATP, Ado/ino and Ino biosensors
into the slice to record the signals during the bath application
of ATP (10–100 lmol/L). We found that about 7% of the
applied ATP was converted to adenosine with a further 2–3%
appearing as inosine (Fig. 7a). This conversion, although
very incomplete compared with the amounts of applied ATP,
nevertheless occurred very rapidly. Interestingly, in the slice
the ATP biosensor only detected around 5% of the bath
applied ATP, suggesting that as much as 80% of the ATP is
broken down and presumably accumulates within the slice as
ADP and AMP.
We made use of a convenient phosphate assay to measure
the catabolism of ATP by the endogenous ectonucleotidases
in the hippocampal slice to test the efﬁcacy of ARL 67156 as
a blocker. At 100 lmol/L, ARL 67156 mediated partial
competitive blockade of the conversion of ATP, giving a
block of some 50% against 10 lmol/L ATP and some 24%
against 100 lmol/L ATP (Figs. 7c and d). Thus, if adenosine
production were to arise from prior ATP release we would






Fig. 7 Rapid but incomplete conversion of ATP to adenosine in the
extracellular space of the hippocampus. (a) Bath application of 100, 30
and 10 lmol/L ATP (indicated by black bars) was rapidly detected as
adenosine and inosine by biosensors within the slice. (b) About 10% of
the applied ATP was converted to adenosine or inosine. However, only
around 5% of the applied ATP can be detected within the slice sug-
gesting breakdown and accumulation of ADP/AMP. (c) Measurement,
via the malachite green assay, of the time-dependent breakdown of
ATP through accumulation of inorganic phosphate (Pi) in a hippo-
campal slice. Application of ARL 67156 substantially lowered the rate
of ATP breakdown but did not abolish it. (d) Summary graph demon-
strating that ARL 67156 acts as a competitive inhibitor of ATP
breakdown and becomes less effective as the concentration of ATP
rises.
Fig. 6 Gap junction hemichannels do not appear to mediate isch-
aemic purine release. The hemichannel blocker carbenoxolone (CBX,
100 lmol/L) depressed the fEPSP, but did not prevent occurrence of
the anoxic depolarisation (dashed vertical line). Adenosine release
was unaltered by CBX. However, ATP release was greatly increased.
Black bar denotes period of ischaemia.
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67156 (100 lmol/L) in slices that had been pre-incubated
with the blocker for at least 15 min. Interestingly, ARL
67156 caused a reduction of the adenosine tone of
110 ± 49 nmol/L (n = 7), suggesting that the basal levels
of adenosine in the slice arise from the breakdown of ATP.
This conﬁrms the observation made in rat by Dulla et al.
(2005) with MK I adenosine sensors, and supports the
conclusions of Pascual et al. (2005) who suggested that
release of ATP from glial cells gives rise to an adenosine tone
in mouse hippocampus.
ARL 67156 caused a modest enhancement of ATP
release following the anoxic depolarisation (Table 1, Fig. 8),
however, it did not reveal any early phase of ATP release
during ischaemia that could conceivably have been hidden
from the ATP biosensor under control conditions by virtue
of efﬁcient or localised catabolism by the ectonucleotidases.
Furthermore, adenosine release during ischaemia was not
signiﬁcantly different from the control in the presence of
ARL 67156 (Table 1, Fig. 8). We therefore conclude that
ATP breakdown (although it can occur and does contribute
to a basal tone of adenosine) does not signiﬁcantly
contribute to the production of extracellular adenosine
during ischaemia.
An intracellular origin for adenosine during ischaemia
As adenosine does not appear to arise from the extracellular
breakdown of ATP, it may well be released directly during
ischaemia. Pre-treatment with the membrane permeable
homocysteine thiolactone is an elegant method that has been
used previously to ‘trap’ intracellular adenosine in the form of
S-adenosyl homocysteate (Lloyd et al. 1993) through the
actions of the intracellular enzyme S-adenosyl homocysteine
hydrolase. We therefore tried the same method to test whether
we could diminish adenosine release during ischaemia.
Homocysteine thiolactone is a small highly reactive
molecule that is electroactive. However, limiting the con-
centration of homocysteine thiolactone to 100 lmol/L
ensured that an extra background current of only a few
hundred pA was seen on the sensors (without the screening
layer even this concentration would have given a current of
several 10s of nA). Pre-treatment with homocyseine thiolac-
tone reduced the adenosine release at all phases during
ischaemia. This was most marked during the PPE (Table 1).
Strangely, homocysteine thiolactone enhanced ATP release
(Table 1).
Equilibrative nucleoside transporters do not mediate
ischaemic purine release
The simplest explanation for our data is that adenosine is
mainly released as adenosine, rather than an upstream
metabolite, and that ATP and adenosine release during and
following ischaemia are essentially independent processes.
We therefore tested whether the application of adenosine
equilibrative transport inhibitors could reduce the release of
adenosine during ischaemia.
Combined application of the equilibrative nucleoside
transport (ENT) inhibitors 10 lmol/L DIPY and 5 lmol/L
NBTI (n = 4; Fig. 6), caused a slow 50% depression of
the fEPSP over the course of around 40 min. We and others
have previously shown that this depression is the result of
an increased tone of extracellular adenosine as a result of
adenosine transport inhibition (Dunwiddie and Diao 1994;
Pearson et al. 2001; Gadalla et al. 2004). We directly
observed this gradual increase in adenosine tone in 2/3
cases with the ado/ino biosensor (Fig. 9a). Once the
depression of the fEPSP had stabilised, we made the slice
ischaemic to observe the effect of these ENT inhibitors on
both ATP and ado/ino release (Fig. 9b). We observed
greatly enhanced accumulation of adenosine during all
phases of release. Overall there was a twofold increase of
adenosine release compared with the control (Fig. 9b,
Table 1). As might be expected the adenosine transport
inhibitors had no signiﬁcant effect on ATP release (Fig. 9b,
Table 1).
Discussion
Our results demonstrate that both ATP and adenosine are
released during ischaemic episodes. However, the timing,
characteristics and mechanisms of ATP and adenosine
release differ dramatically. We shall discuss each in turn,
along with the potential signiﬁcance of purine release during
ischaemia.
The timing and phases of ATP and adenosine release
Whereas adenosine release occurs almost immediately fol-
lowing the onset of hypoxia/ischaemia (Dale et al. 2000;
Frenguelli et al. 2003; Pearson and Frenguelli 2004; Pearson
et al. 2006), ATP release only occurred after the anoxic
depolarisation. The timing of ATP release remained constant
relative to the anoxic depolarisation following treatments that
either speeded (EGTA/zero Ca
2+) or slowed (kynurenic acid/
TTX) its occurrence. Similarly, the time to the anoxic
Fig. 8 Adenosine release during ischaemia does not result from the
breakdown of ATP. Application of 100 lmol/L ARL 67156 enhanced
ATP release during ischaemia (black bar) but had no effect on
adenosine release.
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ATP release still follows this event. ATP release is thus
contingent upon the events that precipitate the anoxic
depolarisation.
We observed two phases of adenosine release: release
during the ischaemic episode followed by a surge in release
on re-oxygenation (the PPE). This is remarkably similar to
the release of adenosine during hypoxia (Frenguelli et al.
2003). During the PPE, adenosine levels could take 15–
20 min to return to the pre-ischaemic baseline and could
underlie the protracted post-ischaemic adenosine-dependent
depression of synaptic transmission observed by Pearson
et al. (2006). There were also two phases of ATP release –
immediate progressive release following the anoxic depo-
larisation, and a surge of release following re-oxygenation.
By contrast to the adenosine PPE, this post-ischaemic ATP
release was short-lived, and ATP levels returned to baseline
within around 5 min following re-oxygenation. In contrast to
the adenosine PPE, this secondary phase of ATP release also
depended upon the occurrence of the anoxic depolarisation –
it was not seen on re-oxygenation following episodes of
ischaemia that were too short to evoke the anoxic depolari-
sation.
The characteristics of ATP and adenosine release
Compared with ATP, much greater quantities of adenosine
(some 17-fold) were produced during and following an
ischaemic episode. Whereas adenosine could reach a maxi-
mum level of 20–30 lmol/L, peak ATP levels were restricted
to 1–2 lmol/L under control conditions. Nevertheless, these
levels are sufﬁcient to activate P2 receptors, and are greatly
in excess of the nanomolar levels reported in a recent
microdialysis study (Melani et al. 2005), which may have
been unable to resolve ATP release around the anoxic
depolarisation.
ATP and adenosine release exhibited different sensitivities
to extracellular Ca
2+. The early phases of ischaemic adeno-
sine release appear to be negatively regulated by extracellular
Ca
2+ – its removal enhanced release – as we initially reported
during hypoxia with MK I sensors (Dale et al. 2000) and as
has been conﬁrmed recently in cultured astrocytes (Martin
et al. 2007). However the post-ischaemic release (the PPE)
was diminished when extracellular Ca
2+ was omitted or
chelated with EGTA. This may result from depletion of the
releasable pool of adenosine by enhanced early release.
Importantly, during prolonged ischaemia in vivo, initially
high levels of extracellular adenosine gradually return to
baseline (Matsumoto et al. 1992). Thus, any treatment
designed to enhance adenosine release, without also ensuring
greater availability, may be of limited neuroprotective value
as it would deplete the adenosine stores more quickly and
lead to lowered neuroprotection during later stages of the
insult.
By contrast, ATP release required extracellular Ca
2+:
release following the anoxic depolarisation was virtually
eliminated by Ca
2+ chelation with EGTA. Interestingly ATP
release remained unaffected by simple removal of extracel-
lular Ca
2+ or the presence of TTX. As both of these
manipulations will block conventional synaptic transmission,
ATP release, although Ca
2+-dependent, may differ mechan-
istically from conventional synaptic vesicular release.
ATP and adenosine release were distinguished further by
their dependence on glutamate receptors. Kynurenic acid
reduced adenosine release early in the ischaemic episode,
consistent with the partial NMDA receptor-dependence of
adenosine release during ischaemia (Pearson et al. 2006). By
contrast ATP release was greatly enhanced by kynurenic
acid. Interestingly, glutamate release is known to occur after
the anoxic depolarisation (Rossi et al. 2000) and could
therefore limit the subsequent amount of ATP release.
Does ATP breakdown contribute to adenosine production
during ischaemia?
A key issue is whether extracellular adenosine during
ischaemia results from direct adenosine release or the prior
release of ATP and its subsequent conversion to adenosine
via the actions of the ectonucleotidases. Previous work from
our laboratory, on the basis of pharmacological inhibition of
(a)
(b)
Fig. 9 Inhibition of nucleoside transport enhances the extracellular
accumulation of adenosine during ischaemia. (a) Combined applica-
tion of the transport inhibitors dipyridamole (DIPY, 10 lmol/L) and
NBTI (5 lmol/L) resulted in a slowly developing inhibition of the fEPSP
which coincided with a slowly increasing signal on the Ado/ino sensor,
demonstrating that the transport inhibitors were effective in raising
extracellular adenosine levels. Magniﬁed examples of the fEPSP are
shown taken before (i) and during (ii and iii) the application of
NBTI/DIPY at the times indicated. (b) Prolonged incubation with DIPY/
NBTI did not prevent release of adenosine during ischaemia (black
bar). Instead ado/ino release was enhanced, whilst there was little
apparent effect on ATP release. The equilibrative nucleoside trans-
porters are thus highly unlikely to mediate the release of adenosine
during ischaemia.
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effect on the hypoxic depression of excitatory synaptic
transmission, argued against the likelihood of released
adenine nucleotides as contributors to extracellular adenosine
during metabolic stress (Pearson et al. 2003; Pearson and
Frenguelli 2004).
Our new data directly suggest adenosine release that is
largely independent from the release of ATP. Firstly,
adenosine release occurred in the apparent absence of any
ATP release; secondly, ATP release and adenosine release
exhibited differential sensitivities to both extracellular Ca
2+
and glutamate receptor blockade; thirdly, ATP release was
only observed following the anoxic depolarisation, whereas
adenosine release exhibited no such dependence on this
event. Any hypothesis that maintained production of
adenosine from prior release of ATP would have to be
consistent with these apparent dissociations of mechanism
between the two processes and would thus be have to be
highly complex.
We have also directly addressed this issue in two further
ways: by examining ATP breakdown in the slice; and by
testing whether inhibition of the ectoATPases can alter ATP
and adenosine release during ischaemia.
As might be expected, ATP conversion to adenosine does
occur in the slice. Although it is rapid, only about 10% of
exogenously applied ATP is converted to adenosine or
downstream purines. This contrasts with the report of
Dunwiddie and colleagues (Dunwiddie et al. 1997) who
indirectly monitored conversion of ATP to adenosine in
hippocampal slices, through adenosine A1 receptor-mediated
activation of a K
+ conductance, and who suggested complete
conversion of ATP to adenosine. The simplest interpretation
of our observation is that in order to see a signal of, for
example, 3 lmol/L adenosine at 5 min of ischaemia (cf.
Table 1) around 30 lmol/L ATP would have to be released –
no ATP is observed at this time point. As the lower detection
limit of the ATP biosensors is below 100 nmol/L it is very
likely that we would detect this hypothesised ATP release if it
were to occur. Similarly, if the adenosine PPE was entirely
the result of the breakdown of ATP we would predict release
at a level in excess of 200 lmol/L to give rise to the observed
adenosine signal (23 lmol/L) – however, only 1.8 lmol/L
is observed (cf. Table 1).
Although the inhibitors of ectonucleotidases are neither
particularly potent nor speciﬁc we have conﬁrmed that ARL
67156 has some useful inhibitory activity against the
ectoATPases in hippocampus (Figs. 7c and d). Although
ARL 67156 reduced the adenosine tone by some 100 nmol/L
and enhanced ATP release during ischaemia, it did not reveal
any hypothesised early phase of ATP release that could give
rise to the early phases of adenosine release during ischaemia.
Even more importantly ARL 67156 had no signiﬁcant effect
on adenosine production during ischaemia. We therefore
conclude that while ATP conversion to adenosine in the
hippocampus undoubtedly occurs, this mechanism is unlikely
to make a signiﬁcant contribution to the large accumulation of
extracellular adenosine during ischaemia
Mechanisms of ATP and adenosine release
The ATP release that we observed is unlikely to result from
the breakdown of cellular membranes and cytolysis: we
could evoke the anoxic depolarisation and ATP release
during conditions (most notably Ca
2+-free aCSF, where it
was directly tested) that permitted full recovery of excitatory
synaptic transmission – an observation inconsistent with
irreversible cellular damage.
Accordingly, there are other possible routes for ATP and
adenosine to cross the plasma membrane during and after the
ischaemic episode: via exocytosis; through a transporter; or
via an open channel (Volterra and Meldolesi 2005; Franke
and Illes 2006). That adenosine release persisted in the
absence of extracellular Ca
2+ and TTX strongly militates
against conventional exocytotic release. However, as ATP
release did exhibit Ca
2+-dependence (despite being TTX-
independent), an exocytotic release mechanism during isch-
aemia remains possible. Glial cells release ATP in the
hippocampus via a SNARE-dependent process (Pascual
et al. 2005), which is converted to adenosine and contributes
to a tone of adenosine in the mouse hippocampus. Our data
also directly demonstrate that ATP breakdown contributes to
an adenosine tone in rat and supports a similar mechanism
for its origin – release from glial cells.
We also tested whether gap junction hemichannels might
contribute to purine release by applying CBX. That adeno-
sine and ATP release persisted (and indeed ATP release was
greatly enhanced by this treatment) strongly suggests that
gap junction hemichannels cannot be responsible for the
release of these molecules during ischaemia (see also Martin
et al. 2007), despite the recent observation that these
channels open under these conditions (Thompson et al.
2006). We cannot, however, eliminate the possibility that
some other large conductance channel activated by the
anoxic depolarisation could contribute to their release,
although P2X7 pores have recently been excluded as
conduits of adenosine release during hypoxia (Martin et al.
2007).
The equilibrative adenosine transporters, in particular
ENT1 and ENT2, are important regulators of extracellular
adenosine (King et al. 2006). We and others have found that
combined application of the transport blockers dipyridamole
and NBTI increased the extracellular adenosine tone, meas-
ured directly in this study, with signiﬁcant A1R-dependent
effects on excitatory synaptic transmission (Dunwiddie and
Diao 1994; Pearson et al. 2001; Gadalla et al. 2004). This
implies a constant cycling of adenosine between the extra-
and intracellular compartments and it has been suggested that
speciﬁc cell types could contribute differentially to the
release and removal of adenosine from the extracellular space
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transport blockers enhanced rather than diminished release of
adenosine during ischaemia is consistent with the suggestion
that equilibrative transporters may limit its accumulation in
the extracellular space (Cunha 2005) and with observations
in vivo (Phillis et al. 1989). However the precise molecular
and cellular mechanism of adenosine release during isch-
aemia remains unresolved, although recent evidence impli-
cates astrocytes as the primary source of adenosine during
hypoxia (Martin et al. 2007). Nonetheless, as adenosine
transport inhibitors are known to be neuroprotective (Noji
et al. 2004), their efﬁcacy likely results from their ability to
dramatically increase levels of extracellular adenosine during
all phases of ischaemia and post-ischaemic recovery.
During ischaemia, glutamate is released via reversed Na
+-
dependent transport (Jabaudon et al. 2000; Rossi et al.
2000). This occurs following the anoxic depolarisation as
neurons become unable to maintain the physiological Na
+
gradients across their membranes (Somjen 2001). This
reversal of the Na
+-gradient could in principle power an
adenosine efﬂux via the Na
+-dependent concentrative trans-
porters (Gray et al. 2004). However, adenosine release
occurs almost immediately following the onset of ischaemia
and presumably well in advance of loss of the normal
transmembrane Na
+ gradients. Thus, although Na
+-depend-
ent efﬂux of adenosine could contribute to later stages of
adenosine release, some other as yet unknown mechanism
must underlie its release during the earlier stages of
ischaemia.
The signiﬁcance of tonic and evoked ATP and adenosine
release
Numerous estimates of basal extracellular adenosine con-
centration have set the value at between 30 and 300 nmol/L
(Fredholm et al. 2001). This would provide tonic activation
of at least the high afﬁnity and high abundance A1 receptor.
That such a tone exists is amply documented by the many
studies showing enhancements of hippocampal synaptic
transmission by A1R antagonists (Bauman et al. 1992; Dulla
et al. 2005; Pascual et al. 2005; Studer et al. 2006) or by
adenosine deaminase (Gadalla et al. 2004). The extent of the
tone and subsequent enhancement by antagonists may be
determined by the particular experimental setup (Moore
et al. 2003; Kukley et al. 2005). Use of ARL 67156 in our
study suggests a basal tone of adenosine of approximately
100 nmol/L. Increases in basal tone could be detected (with
consequent depression of synaptic transmission) in the
presence of adenosine uptake blockers (Fig. 9). However,
30 min after the end of ischaemia, adenosine levels were still
elevated, a ﬁnding consistent with our previous observations
(Pearson et al. 2006).
In vivo, basal ATP levels have been estimated to be as low
as a few nmol/L (Phillis and O’Regan 2003; Melani et al.
2005), which is below the level of detection in the present
study. Accordingly, it is not clear whether this low basal level
of ATP is sufﬁcient to exert any inﬂuence via P2 receptors
(Dulla et al. 2005; da Silva et al. 2005).
Notwithstanding the vexed issue of sources of purines
during metabolic stress, it is surprising that brain tissue
should release ATP at a time when cellular levels of ATP are
severely depleted. This ATP release may well be signiﬁcant
in the pathology of stroke as it is likely to deplete further the
intracellular stores of ATP, delay their recovery following
re-oxygenation and initiate potentially injurious signalling
cascades in neighbouring tissue. This is especially pertinent
in the context of human anoxic depolarisation-like events
(peri-infarct depolarisations) which spread through the
penumbra enlarging the area of damaged brain tissue
(Fabricius et al. 2006).
Accordingly, P2 receptor antagonists are neuroprotective
in a range of models (Franke and Illes 2006) implying that
ATP release and subsequent activation of P2 receptors, which
may occur for some time after the end of ischaemia, may be
harmful to cells. Post-ischaemic up-regulation of the ecto-
nucleotidases responsible for metabolism of extracellular
ATP has been described (Braun et al. 1998) which may
represent an adaptive mechanism to reduce the damaging
effects of ATP release in further ischaemic attacks. In
contrast, proliferation of astrocytes or migration of microglia
in response to ATP may provide trophic support for injured
tissue (Franke and Illes 2006).
Adenosine release has been reported to be neuroprotective
through its action on A1 receptors, but damaging through
A2A receptors (Cunha 2005). Our data demonstrate that
adenosine release is maintained well after the ischaemic
insult has terminated and indeed involves a surge of release
following re-oxygenation (the PPE). The signiﬁcance of the
PPE remains an intriguing mystery as we have yet to ﬁnd a
means to manipulate it selectively. Nevertheless, a PPE-like
mechanism in vivo could be of signiﬁcance around the
boundary of an infarction. In this peripheral zone the
enhanced adenosine release could assist reperfusion by
acting as a vasodilatator (Meno et al. 1993) and limit the
spread of glutamatergic excitation (Pearson et al. 2006).
In conclusion, the rapid ischaemic release of adenosine
and the subsequent release of ATP during the anoxic
depolarisation are governed by distinct temporal and mech-
anistic processes. The implications of purine release for post-
ischaemic neuronal function are likely therefore to depend
upon the balance between beneﬁcial and damaging cellular
cascades initiated by the two purines. Understanding how to
tip the balance in favour of beneﬁt might be useful in the
treatment of disorders of the human CNS.
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The following material is available to this paper online.
Fig. S1 Representative control experiment illustrating the timings
of the measurements described in the text and in Table 1.
Table S1 Mean time taken (±SEM) to reach the anoxic depolari-
sation (AD), and total duration of the ischaemic episodes delivered
under the various experimental conditions.
This material is available as part of the on line article from http://
www. blackwell-synergy.com.
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